Ppreferentially expressed antigen in melanoma (PRAME) t cell receptors and methods of use thereof

MYPI2025005476A0Undetermined Publication Date: 2021-07-24REGENERON PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025005476
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-01-24
Filing Date
2021-01-22
Publication Date
2021-07-24
Patent Text Reader

Abstract

The present invention provides isolated T cell receptors (TCRs) that specifically bind to an HLA-displayed cancer testis antigen preferentially expressed antigen in melanoma (FRAME) peptide, as well as therapeutic and diagnostic methods of using those isolated TCRs. No suitable figure.
Need to check novelty before this filing date? Find Prior Art